Medico Remedies Reports Stable Q3 FY24-25 Results Amid Concerns Over Income Sources

Medico Remedies, a microcap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The results, declared on February 5, 2025, indicate a stable financial performance for Q3 FY24-25. Notably, the company's score has undergone an adjustment, moving to 3 from a previous score of -7 over the last three months.
The financial data reveals that Medico Remedies achieved a Profit After Tax (PAT) of Rs 2.62 crore, reflecting a significant year-on-year growth of 80.7%. This positive trend in PAT suggests a favorable near-term outlook for the company's profitability. Additionally, net sales for the quarter reached Rs 39.49 crore, marking a year-on-year increase of 32.65%, further indicating a robust sales trajectory.

However, it is important to note that a considerable portion of the company's income, specifically 40.86% of Profit Before Tax (PBT), is derived from non-operating activities. This reliance on non-business income raises concerns regarding the sustainability of its business model.

For more insights on Medico Remedies and its financial performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.